Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways

Regardless of the presence or absence of specific diagnostic mutations, many cancer patients fail to respond to EGFR-targeted therapeutics, and a personalized approach is needed to identify putative (non)responders. We found previously that human peripheral blood and EGF can modulate the activities...

Descrición completa

Detalles Bibliográficos

Principais autores:	Dmitri Kamashev, Nina Shaban, Timofey Lebedev, Vladimir Prassolov, Maria Suntsova, Mikhail Raevskiy, Nurshat Gaifullin, Marina Sekacheva, Andrew Garazha, Elena Poddubskaya, Maksim Sorokin, Anton Buzdin
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-08-01
Series:	Cells
Assuntos:	EGFR HER-targeted cancer therapy human blood serum cetuximab erlotinib EGF
Acceso en liña:	https://www.mdpi.com/2073-4409/12/16/2022
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!